Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This global clinical trial which evaluates the efficacy and safety of TLX101-Tx, an investigational radiopharmaceutical therapy, in combination with lomustine versus lomustine alone in adult patients with first recurrence of glioblastoma. TLX101-Tx delivers targeted radiation to glioblastoma cells. The trial is conducted in two parts: Part 1 assesses safety and radiation dosing; Part 2 is a randomized comparison of the combination therapy against standard care.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony wcześniej nowotwór mózgu typu glejak (glioblastoma)
- •Obrazowe potwierdzenie pierwszego nawrotu choroby co najmniej 3 miesiące po zakończeniu poprzedniego leczenia
- •Wiek 18 lat lub więcej
- •Dobra ogólna kondycja zdolna do tolerowania badania (status ECOG 0-2)
- •Prawidłowe funkcje wątroby, nerek i krwiotwórczego szpiku kostnego
- •Zdolność do zrozumienia badania i zastosowania się do jego wymogów
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 11, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (9)
Gold Coast University Hospital
Gold Coast, Australia
Austin Health
Melbourne, Australia
Sir Charles Gairdner Hospital
Perth, Australia
Royal Adelaide Hospital
Adelaide, Australia
Johannes Kepler University
Linz, Austria
UZ Leuven
Leuven, Belgium
Chu of Liège
Liège, Belgium
The Netherlands Cancer Institute (NKI)
Amsterdam, Netherlands
UMC Utrecht
Utrecht, Netherlands
Trial contact
Clinical Project Manager
Back-up Clinical Project Manager
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/12/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.